Abstract C108: Employer-based implementation of Galleri multi-cancer early detection testing to address socioeconomic disparities in receipt of screening
Authors: Jamal Ahmedin , Winn Robert , Cance William , Johnson Tim , Lilyestrom Wayne 
Published: December 2023

Abstract
Background: Multi-cancer early detection (MCED) tests are designed to complement USPSTF-recommended screening to detect many cancers for which no established screening methods exist. Implementing an MCED test as an employee benefit offers an approach to detect cancers for which there is no screening method and to address socioeconomic disparities in receipt of screening. Methods: Galleri, a blood-based MCED test, was implemented in companies with employees in industrial/manufacturing spaces. We approximated educational attainment (≤12 years vs &gt;12 years) as a dichotomous measurement of socioeconomic status (SES). The industrial locations with employees of lower SES were selected based on data from individual companies and focused on diverse employees, low rates of preventive screenings, high healthcare costs, and low health literacy. Enrollment was accomplished through on-site events where consent and blood draws were available, as well as telehealth visits with subsequent blood draws. Results: From October 2021 to May 2023, 812 Galleri MCED tests were administered in a population of industrial employees. Of the participants, 317 (39%) were female and 495 (61%) were male, and the median age was 54 years. A total of 217 (27%) participants were aged 35-49, 531 (65%) were aged 50-64, and 62 (8%) were aged 65-79. Four tests returned a cancer signal detected result with a predicted cancer signal origin of colorectal (n=2), anus (n=1), and breast (n=1). Of the four participants with a cancer signal detected result, three were in the 50-64 age group and one was in the 65-79 age group. The breast cancer diagnosis was confirmed, and follow-up is ongoing in the participants with a cancer sign origin of colorectal and anus. A total of 676 (83%) tests were administered during 9 on-site events and 136 (17%) were obtained by telehealth visits. Factors that were important for taking the Galleri test were onsite events, trusted long-time employees onsite that spoke their language and helped translate the request form, explanation of the test in their native language, and the ability to administer the test without a computer or other digital requirements. Conclusion: MCED testing may be implemented more widely among individuals of lower SES when it is included as an employee benefit with in-person communication by trusted employee messengers and by limiting digital requirements. Supporting the unique needs of individuals before administering an MCED test and those with a cancer signal detected result are important steps for improving access and achieving diagnostic resolution.
Citation Format: Ahmedin Jamal, Robert Winn, William Cance, Tim Johnson, Wayne Lilyestrom. Employer-based implementation of Galleri multi-cancer early detection testing to address socioeconomic disparities in receipt of screening [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C108.